BioAge Labs Plunges Over 60% After Novo’s ZEUS Trial Failure — Citi Says the Sell-Off Is Overdone
BioAge Labs shares fell over 60% after Novo Nordisk’s ZEUS trial failed to cut MACE. Citi says the sell-off is excessive despite negative ASCVD impact.
NOTRELOAD AI
Private-Equity Firm KKR Near Agreement to Take Medical-Device Maker Integer Holdings Private
KKR nears deal to take Integer Holdings private at $127/share. Announcement possible next week; values the medical-device CDMO at ~$4.3B.
T-Mobile and Deutsche Telekom Merger Hits Roadblock Over Shareholder and U.S. Concerns
T-Mobile and Deutsche Telekom merger talks pause as non-controlling shareholders oppose the deal and U.S. regulators seek revenue guarantees.
NXP in Advanced Talks to Buy AI Chipmaker Ambarella
NXP Semiconductors is in talks to acquire Ambarella for ~$3.3B, boosting its AI camera and computer-vision chips for self-driving cars, FT says.
Neurocrine Stock Weak Despite Strong Q2 Beat and Raise; Analysts Call Dip “Overdone”
Neurocrine reported $959M Q2 revenue (+39%) and raised Ingrezza guidance. Stock fell on short-term concerns, but analysts call the dip overdone and raise targets.
Roblox Stock Hit by Wave of Analyst Downgrades After Weak Guidance
Monetization slows, visibility drops, and price targets are cut.